Latest news with #SID
&w=3840&q=100)
Business Standard
12 hours ago
- Business
- Business Standard
Motilal Oswal MF launches BSE 1000 Index Fund: Here's all you need to know
Motilal Oswal BSE 1000 Index Fund: Motilal Oswal Mutual Fund has launched its Motilal Oswal BSE 1000 Index Fund, an open-ended scheme tracking BSE 1000 Total Return Index. The new fund offer (NFO) will open for subscription today, June 5, 2025, and close on Thursday, June 19, 2025. The fund provides broad-based exposure to India's equity markets by tracking the BSE 100 Total Return Index, which covers around 94 per cent of the country's listed market capitalisation. It includes companies across large, midcap, smallcap, and micro-cap segments, representing diverse sectors and industries. The index offers a mix of established companies as well as fast-growing smaller firms from 22 different sectors. To reduce concentration risk, the top 10 stocks are capped at around 33 per cent of the total weight. It also includes micro-cap companies, whose market size and trading activity have grown from 5 times and 14 times, respectively, over the last five years. The index is passively managed, based on free-float market value, and is rebalanced twice a year. According to the Scheme Information Document (SID), the scheme aims to provide returns that, before expenses, correspond to the total returns of the securities as represented by BSE 1000, subject to tracking errors. However, there can be no assurance or guarantee that the investment objectives of the scheme will be achieved. According to SID, if the units are redeemed on or before 15 days from the day of allotment, an exit load of 1 per cent will be charged. However, no exit load will be charged if units are redeemed after 15 days from the date of allotment. According to the riskometer, the principal invested in the scheme will be at very high risk. ALSO READ | Swapnil Mayekar, Dishant Mehta, and Rakesh Shetty are the designated fund managers for the schemes. Pratik Oswal, chief of passive business at Motilal Oswal Asset Management Company (MOAMC), said that this fund provides a diversified exposure to India's corporate sector and is a natural evolution for investors seeking a passive investment option. "As pioneers in passive investing, our goal is to offer simple, low-cost, and scalable investment options, and this launch aligns with that objective," he added. During the NFO and ongoing basis, investors can invest a minimum amount of ₹5,000 and in multiples of ₹1 thereafter. The minimum amount and frequency vary for investments through a Systematic Investment Plan (SIP). Motilal Oswal BSE 1000 Index Fund: Who should invest? According to the SID, the fund is suitable for investors seeking long-term capital growth and return that corresponds to the BSE 1000 Total Return Index, subject to tracking error. However, investors should consult their financial advisers if in doubt about whether the product is suitable for them.
Medscape
a day ago
- Health
- Medscape
Current and Future AI Uses in Dermatology: An Expert's View
Roxana Daneshjou, MD, PhD, is one of the leading experts on artificial intelligence (AI) in American dermatology. Daneshjou, assistant professor of biomedical data science and dermatology at Stanford University, Stanford, California, leads landmark AI studies, is an associate editor of the journal NEJM AI , and gives presentations about the topic, including one at the recent Society for Investigative Dermatology (SID) 2025 annual meeting where she starkly warned colleagues that 'dermatologists who use AI will replace dermatologists who don't.' Roxana Daneshjou, MD, PhD So one could assume that Daneshjou embraces AI in her clinical practice. But she doesn't — not quite yet. While AI is helpful with office tasks that involve writing, she said, it's not currently good enough at handling tasks, such as evaluating skin lesions or helping solve diagnostic riddles. 'You should only use it for tasks where you can easily catch errors and rectify them. You shouldn't use it when you're not sure of the answer or the next step because you could be badly misled,' she said in an interview with Medscape Medical News . But just wait. 'Eventually, once we have valid, well-validated AI tools that can help with diagnosis and triage, they're going to become essentially standard of care,' Daneshjou said. The following are excerpts from the interview with Daneshjou about the present and future of AI in dermatology. What do you mean when you say, 'Dermatologists who use AI will replace dermatologists who don't'? Daneshjou: That's actually a rehashed phrase originally coined by Curt Langlotz, a radiologist who made the same claim about radiologists. The point is that dermatologists aren't going anywhere. AI is not replacing dermatologists. It's that dermatologists who use AI will replace dermatologists who don't. Will some dermatologists be left behind? Daneshjou: Medicine always evolves. There was a time when we didn't have advanced imaging technologies like CT scans and MRIs. And think about how many dermatologists now use electronic health records (EHRs) vs writing everything down by hand. There are still some people writing things by hand, but physicians who can use EHRs have largely replaced those who can't. This isn't a new phenomenon. Whenever new technology comes along, it becomes incorporated into medical practice, and those who learn to adapt and adopt it eventually replace those who don't. Is there fear and denial in the dermatology community about AI? Daneshjou: There's fear, but there's also enthusiasm — sometimes enthusiasm to the point of using things that aren't ready for prime time. In my SID talk, I discussed how it's not safe to use large language models [AI] — LLMs — for any clinical task where you don't know the answer or can't validate it quickly. These models can have errors that are difficult to catch because the outputs look so convincing. Can you give an example of how using LLMs clinically might get a dermatologist in trouble? Daneshjou: In my presentation, I showed AI being asked to calculate a RegiSCAR score for a patient. It gives an output that looks really convincing but has some of the scores wrong. If you didn't know the RegiSCAR score yourself, you might not catch that mistake. Similarly, if you ask about medication dosing, sometimes AI gets it right. But research papers show it can get dosing wrong. If you're not certain of the answer, you shouldn't use an LLM for that task. That's different from giving it bullet points and saying, 'Follow these bullet points to draft a prior authorization letter' or 'Write an after-visit summary for my patient' about a disease you're well-versed in, and you can verify [the text] for accuracy. Are there reliable clinical uses for AI now? Daneshjou: First, I should note that publicly facing models aren't Health Insurance Portability and Accountability Act (HIPAA)–compliant, so you have to be careful about putting patient information in them. Some institutions like Stanford have HIPAA-compliant versions internally. I'd be very wary of using these models for diagnosis and treatment because they can say things that are wrong. I've heard dermatologists say they've put patient images into these models to get a differential diagnosis, which I would strongly advise against — both for HIPAA concerns and because the outputs aren't reliable. What about 'vision language' models (VLMs) in dermatology that are trained on skin images and could potentially be used for tasks such as identifying lesions? Daneshjou: The VLMs we've tested perform worse than the LLMs. They're even more in the research realm. Are current AI systems actually good at categorizing skin lesions? There are many papers claiming they're good, but there's not much prospective trial data validating that performance. We need more trial data proving that a particular model will continue to perform well in a clinical setting. So AI isn't ready for prime time in diagnosis and treatment? Daneshjou: That's correct. It's more useful in a supportive role — helping with writing or editing text. You worked on a 'red teaming' event that assigned attendees — engineers, computer scientists, and health professionals such as dermatologists to assign medical tasks to AI and ask questions. The results were published in Nature in March 2025. What did you discover? Daneshjou: We found that across all models tested, there was an error rate of around 20%. As our chief data scientist at Stanford likes to joke, 'You can use large language models for any task where a 20% error rate is acceptable.' Where do you think AI and dermatology are headed next? Daneshjou: Image-based models will eventually get good enough to earn US Food and Drug Administration clearance. But my concern is this will happen without the creators having to prove the models work across diverse skin tones — an incredibly important part of validation. Our research has shown that most image-based AI models exclude diverse skin tones in their training and testing. We're also going to see more multimodal models — ones that incorporate diverse information like images, text, and molecular data — to provide outputs or risk assessments. That's where AI is heading generally, not only just focusing on text or images alone but also taking information from multiple modalities the way humans do. How often do you use AI in your clinical practice? Daneshjou: Not very much. I run a research lab, so I use it extensively in research. I've used it to help with grant writing and to analyze recommendation letters I've written, asking it to identify weaknesses so I can improve them. Clinically, I've shown my nurse how to use our secure AI to draft prior authorization letters or rebuttals to insurance [rejections]. But otherwise, I don't really use it in clinic. You've discussed how AI handles clinical vignettes vs real patients. What should dermatologists understand about this? Daneshjou: Headlines often misrepresent reality. They'll say, 'AI models can diagnose patients.' But in reality, these models were given very nicely packaged vignettes and were able to provide a diagnosis. Patients don't come as nicely packaged vignettes. In real clinical practice, I have to ask, 'What's going on?' I have to do the skin check, identify lesions, gather history, and ask about duration, symptoms, occupation, and sun exposure. I have to collect all this information and make a judgment. Sometimes, the history doesn't match what you see, so you have to use clinical reasoning. This kind of clinical reasoning isn't what they're testing in research papers that claim AI can diagnose patients. Would you recommend using AI at all for generating differential diagnoses? Daneshjou: I'm not using AI just to use it. I need a specific reason why I think it will help me. For example, if I'm writing a grant and want a summary of one of my own research papers, I might ask it to write a first draft that I can edit because I know my own research well enough to verify what's correct. But I'm not using it to develop differentials for my patients. What would you advise dermatologists who want to adapt to AI but don't know where to start? Daneshjou: The American Academy of Dermatology (AAD) has AI boot camp videos. At the annual AAD meetings, the AAD offers educational sessions on AI. If you look in the Journal of the American Academy of Dermatology , there are Continuing Medical Education reviews that the AAD's Augmented Intelligence Committee has written to educate dermatologists about AI technologies and what to watch for. A few years ago, this content was sparse. But there's been a concerted effort to create educational materials for dermatologists. What would you tell dermatologists who are agonizing about AI? Daneshjou: I see people posting on LinkedIn what I would call outrageous claims based on research papers. They'll say, 'This research paper shows we have autonomous AI agents that can treat patients,' but when you read the actual paper, it doesn't show that at all. Often, the hype doesn't match the reality on the ground. And what about those who think AI is overblown and not worth worrying about? Daneshjou: Claims about AI replacing physicians or dermatologists are indeed overblown. But this is definitely something dermatologists will have to adapt to. It's eventually going to become part of practice in some ways.
Yahoo
16-05-2025
- Health
- Yahoo
Amorepacific and Johns Hopkins School of Medicine's Joint Research Program 'NBRI' Participants Present Latest Findings
Skin anti-aging and immunity effects of Amorepacific's two proprietary ingredients, 'RE.D Flavonoid' and 'Senomune' revealed at the 2025 SID Annual Meeting SEOUL, South Korea, May 16, 2025 /CNW/ -- Amorepacific has demonstrated the efficacy of its two proprietary ingredients in improving skin aging and immune response through the NBRI program, jointly operated with Johns Hopkins School of Medicine. The findings were presented at the 2025 SID (Society for Investigative Dermatology) Annual Meeting in San Diego, California, last week. NBRI (New Beauty Research Initiative) is a collaborative research program that Amorepacific has maintained with the Department of Dermatology at Johns Hopkins School of Medicine since 2022. The two organizations conduct multifaceted research cooperation on skin aging. At this year's SID meeting, NBRI program participants Professor Anna Chien's research team presented the efficacy of Amorepacific's bio-flavonoid ingredient, RE.D Flavonoid, and Professor Martin Alphonse's research team presented the benefits of the green tea-derived ingredient, Senomune. Professor Anna Chien's team confirmed that RE.D Flavonoid, derived from the camellia plant, effectively improves photo-aging symptoms on the face and neck area without irritation. Notable improvements were observed across significant signs of skin aging, including fine lines, skin texture, pores, radiance, and pigmentation, with substantial changes in skin texture and radiance appearing from the eighth week of use. This research was based on long-term results from North American consumers of diverse ethnicities who used RE.D Flavonoid for six months. The study indicates that RE.D Flavonoid works by blocking signal transmission in skin aging and inhibiting collagen damage, which is crucial for skin elasticity. Professor Martin Alphonse's team revealed that Senomune, a saponin component from green tea extract, mitigates immune cell damage and inflammatory responses caused by particulate matter (PM). The team also confirmed the potential for Senomune to reduce immune aging and chronic inflammatory reactions due to external environmental factors by balancing the metabolic functions of immune cells. This research was conducted using peripheral blood mononuclear cells (PBMC) from humans, and researchers observed reduced stress responses in immune cells to environmental harmful elements in groups pre-treated with the ingredient. Dr. Suh Byung-fhy, CTO and Head of Amorepacific's R&I Center, stated, "The ongoing NBRI collaborative research program for Skin Longevity of our global customers provides a valuable opportunity to demonstrate the scientific excellence of Amorepacific's slow-aging skincare technology," adding, "Amorepacific will continue to focus on beauty solution research aimed at activating the skin's fundamental recovery capabilities beyond mere symptom improvement." The Society for Investigative Dermatology (SID) is an organization dedicated to advancing the sciences relevant to skin disease and has held annual meetings since its establishment in 1937. At this year's 82nd conference, more than 1,600 researchers, clinicians, and dermatology residents from around the world gathered to present over 1,200 of the latest skin research findings. View original content to download multimedia: SOURCE Amorepacific View original content to download multimedia:
Cision Canada
16-05-2025
- Health
- Cision Canada
Amorepacific and Johns Hopkins School of Medicine's Joint Research Program 'NBRI' Participants Present Latest Findings
Skin anti-aging and immunity effects of Amorepacific's two proprietary ingredients, 'RE.D Flavonoid' and 'Senomune' revealed at the 2025 SID Annual Meeting SEOUL, South Korea, May 16, 2025 /CNW/ -- Amorepacific has demonstrated the efficacy of its two proprietary ingredients in improving skin aging and immune response through the NBRI program, jointly operated with Johns Hopkins School of Medicine. The findings were presented at the 2025 SID (Society for Investigative Dermatology) Annual Meeting in San Diego, California, last week. NBRI (New Beauty Research Initiative) is a collaborative research program that Amorepacific has maintained with the Department of Dermatology at Johns Hopkins School of Medicine since 2022. The two organizations conduct multifaceted research cooperation on skin aging. At this year's SID meeting, NBRI program participants Professor Anna Chien's research team presented the efficacy of Amorepacific's bio-flavonoid ingredient, RE.D Flavonoid, and Professor Martin Alphonse's research team presented the benefits of the green tea-derived ingredient, Senomune. Professor Anna Chien's team confirmed that RE.D Flavonoid, derived from the camellia plant, effectively improves photo-aging symptoms on the face and neck area without irritation. Notable improvements were observed across significant signs of skin aging, including fine lines, skin texture, pores, radiance, and pigmentation, with substantial changes in skin texture and radiance appearing from the eighth week of use. This research was based on long-term results from North American consumers of diverse ethnicities who used RE.D Flavonoid for six months. The study indicates that RE.D Flavonoid works by blocking signal transmission in skin aging and inhibiting collagen damage, which is crucial for skin elasticity. Professor Martin Alphonse's team revealed that Senomune, a saponin component from green tea extract, mitigates immune cell damage and inflammatory responses caused by particulate matter (PM). The team also confirmed the potential for Senomune to reduce immune aging and chronic inflammatory reactions due to external environmental factors by balancing the metabolic functions of immune cells. This research was conducted using peripheral blood mononuclear cells (PBMC) from humans, and researchers observed reduced stress responses in immune cells to environmental harmful elements in groups pre-treated with the ingredient. Dr. Suh Byung-fhy, CTO and Head of Amorepacific's R&I Center, stated, "The ongoing NBRI collaborative research program for Skin Longevity of our global customers provides a valuable opportunity to demonstrate the scientific excellence of Amorepacific's slow-aging skincare technology," adding, "Amorepacific will continue to focus on beauty solution research aimed at activating the skin's fundamental recovery capabilities beyond mere symptom improvement." The Society for Investigative Dermatology (SID) is an organization dedicated to advancing the sciences relevant to skin disease and has held annual meetings since its establishment in 1937. At this year's 82nd conference, more than 1,600 researchers, clinicians, and dermatology residents from around the world gathered to present over 1,200 of the latest skin research findings.
Yahoo
11-05-2025
- Business
- Yahoo
Companhia Siderurgica Nacional (SID) Q1 2025 Earnings Call Highlights: Strong EBITDA Growth ...
Release Date: May 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Companhia Siderurgica Nacional (NYSE:SID) reported a 28% increase in EBITDA for the quarter, demonstrating strong operational efficiency and market dynamism. The company successfully reduced its net debt by 3.6 billion, improving its leverage ratio to 3.33 times. Record sales were achieved in the mining segment due to favorable weather conditions and operational efficiency. The steel segment saw an 8% increase in sales compared to the first quarter of the previous year, supported by a 2.4% price increase. The logistics and energy segments showed significant growth, with a 16% increase in rail shipments and a 101% rise in EBITDA in the energy sector. The company faces significant challenges from unregulated imports, particularly from China, which are impacting local market competition. High interest rates in Brazil are putting pressure on financial expenses and cash generation, affecting overall profitability. The steel segment is under pressure from subsidized imports, making competition difficult and affecting pricing strategies. There is a lack of effective government measures to control the influx of imported steel, which continues to grow. The company is operating in a challenging macroeconomic environment with high interest rates and inflation concerns, impacting investment and operational continuity. Warning! GuruFocus has detected 7 Warning Signs with SID. Q: Can you explain the company's leverage strategy and expectations for 2026 and 2027, especially with the planned CapEx increase? A: Marco Abelo, IRO, explained that while the company has not provided specific guidance for 2026 and 2027, they are managing CapEx critically, focusing on projects crucial for transformation, particularly in steel and mining. The company aims to maintain leverage below 3 times, even without considering infrastructure projects. They expect significant improvements in cash generation and operational results, which should naturally reduce leverage over the next two years. Q: How is the company dealing with the competitive pressure from Chinese imports, and what are the expectations for domestic steel prices? A: Martinez, CEO, highlighted the challenges posed by Chinese imports, which have been increasing despite government efforts to address anti-dumping issues. The company is focusing on cost management, product diversification, and operational excellence to maintain competitiveness. They expect stable or slightly higher prices in the domestic market, with a focus on maintaining profitability. Q: What is the outlook for margins in the steel segment given the current macroeconomic conditions? A: Martinez, CEO, stated that despite high interest rates and import levels, the company aims to maintain stable margins by focusing on operational excellence, cost reduction, and strategic pricing. They expect costs to decrease in the coming quarters, which should support margin stability. Q: Are there other project finance opportunities similar to the CEEE project that could aid in deleveraging? A: Marco Abelo, IRO, confirmed that the company is exploring additional project finance opportunities, including projects in steel and mining. These projects are expected to contribute to deleveraging over time, although they require careful structuring and time to implement. Q: How does the company plan to manage capital allocation given the current interest rate environment and tariff discussions? A: Marco Abelo, IRO, explained that the company is being very selective with capital allocation, focusing on projects that enhance efficiency and profitability. They are maintaining a controlled CapEx and prioritizing projects that offer significant returns, despite the challenging interest rate environment. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
